Top Peptide Synthesis Companies

Peptide Synthesis Market size was valued at USD 791.12 Million in 2024 and is poised to grow from USD 893.97 Million in 2025 to USD 2376.57 Million by 2033, growing at a CAGR of 13% during the forecast period (2026–2033).

Peptide synthesis is a capital extensive business with a high entry barrier in terms of regulations and approvals. The market is dominated by major global players with many contract manufacturing companies expanding their operations in developing regions due to the low production cost advantages. Companies are spending significant resources on development and approval of new peptide based diagnostic and therapeutic products. Hence R&D initiatives and technology collaborations are the key business strategies witnessed in the market. 'MERCK KGAA ', 'THERMO FISHER SCIENTIFIC ', 'GENSCRIPT BIOTECH CORPORATION ', 'BACHEM HOLDING AG ', 'KANEKA CORPORATION ', 'BIOTAGE AB ', 'SYNGENE INTERNATIONAL LIMITED ', 'MESA LABORATORIES, INC. ', 'CEM CORPORATION ', 'PROTEOGENIX ', 'BIO-SYNTHESIS INC. ', 'DALTON PHARMA SERVICES ', 'AAPPTEC ', 'VIVITIDE ', 'ANYGEN CO., LTD. ', 'ADVANCED CHEMTECH ', 'LUXEMBOURG BIO TECHNOLOGIES LTD. ', 'JPT PEPTIDE TECHNOLOGIES GMBH ', 'AMBIOPHARM INC. ', 'AURIGENE PHARMACEUTICAL SERVICES LTD'

Imaging technology demand is growing substantially for accurate diagnosis of chronic diseases. Peptide synthesis market was valued at more than USD 30 billion in 2023. Use of biosensors and biomarkers for both invasive and non-invasive diagnosis is also very prevalent. Peptide based biosensors and biomarkers are experiencing massive demand growth fueling the market for peptide synthesis.

Substantial Growth in Pharmaceutical Industry: Pharmaceutical industry demand is increasing steadily, and R&D spending is increasing at an even higher growth rate. According to a survey conducted by the US Censos Bureau in 2020, expenditure on pharmaceutical R&D has increased by more than 25% in the past decade. This is providing more budget for development of peptide synthesis solutions and processes.

North America is dominating the global peptide synthesis market due to higher healthcare expenditure and developed healthcare service offerings. North America is home to some of the largest pharmaceutical companies in the world. These players are investing significantly in R&D with the cumulative R&D cost of the pharmaceutical companies in the US accounting to more than USD 95 billion in 2023. The increasing prevalence of chronic diseases in North America is also increasing the demand for peptide synthesis in the region. In the US, more than half of the adult population was reported to suffer from at least one chronic disease.